Exagen Inc. (XGN): Multiplikator Forward P/S
Exagen Inc. is protected by lupus diagnostic patents and strict FDA oversight. The projected P/S dynamics allow for an assessment of market expectations, while 1.50 captures the current value of the indicator. Test centralization ensures business scalability without inflating headcount, and the demand for the AVISE system drives current growth despite the costs associated with onboarding new clinics.
Rincian metrik komprehensif lan analitis Exagen (XGN)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- rincian utang lan likuiditas:
Rasio Total Utang marang Ekuitas Exagen Inc.|XGN - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal exagen.com|XGN - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Exagen Diagnostics|XGN - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Exagen Inc.|Indikator likuiditas cepet exagen.com
- rincian asil keuangan lan kelipatan valuasi:
XGN - Asil keuangan resik|Bathi mangsa ngarep Exagen Inc.|XGN - Pangali rega marang bathi|Pangali Forward P/E Exagen Diagnostics|XGN - Rasio rega marang wutah bathi resik|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Exagen Diagnostics|XGN - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Exagen Inc.|XGN - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan exagen.com|XGN - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Exagen Inc.
- rincian pendapatan lan dodolan:
Analisis komprehensif perusahaan:XGN (Exagen Inc)
Exagen Inc. diversification through a network of rheumatological pathology diagnostic clinics stabilizes revenue, which directly impacts the calculated 1.50 coefficient. Analyzing the issuer's forward P/S, an investor assesses the company's market value relative to expected sales, where an increasing multiple signals positive business growth forecasts while simultaneously raising the risk of a market correction for the asset.
Analisis pesaing Exagen Inc.
Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS - Multiplikator Forward P/S|RVTY (Revvity) - Multiplikator forward rega marang pendapatan|Bio-Rad - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan anbio.com|Multiplikator Forward P/S Sotera Health Company|Rasio rega marang prakiraan pendapatan QuidelOrtho (QDEL)|OPK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|caredx.com - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Maravai LifeSciences Corp (MRVI)|FLGT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Rasio rega marang prakiraan pendapatan|OSUR: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan MDXH|LUCD - Prakiraan rega marang pendapatan|Rasio rega marang prakiraan pendapatan Prenetics (PRE)|Rasio rega marang prakiraan pendapatan IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Multiplikator forward rega marang pendapatan|prophaselabs.com - Rasio rega marang prakiraan pendapatan|AIMD - Rasio rega marang prakiraan pendapatan|Co-Diagnostics Inc (CODX) - Multiplikator forward rega marang pendapatan|HSCS: Multiplikator Forward P/S|BMRA - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CDIO|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep onconetix.gcs-web.com ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs (VRAX)|Rasio rega marang pendapatan sing dikarepake BJDX|Rasio rega marang prakiraan pendapatan Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc
